Long-Term Outcomes Following Sirolimus Conversion after Renal Transplantation

References

• Bolin P, Shihab FS, Mulloy L, et al. (2008). Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results. Transplantation, 86, 88–95
   PubMed Web of Science ®Google Scholar
• Chhabra D, Alvarado A, Dalal P, et al. (2013). Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. Amer J Transplant, 13, 2902–11
   PubMed Web of Science ®Google Scholar
• Chi H. (2012). Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol, 12, 325–38
   PubMed Web of Science ®Google Scholar
• Cosio FG, Amer H, Grande JP, et al. (2007). Comparison of low versus high tacrolimus levels in kidney transplantation: Assessment of efficacy by protocol biopsies. Transplantation, 83, 411–16
   PubMed Web of Science ®Google Scholar
• Diekmann F, Andres A, Oppenheimer F. (2012). mTOR inhibitor-associated proteinuria in kidney transplant recipients. Transplant Rev, 26, 27–9
   Web of Science ®Google Scholar
• Ekberg H, Tedesco-Silva H, Demirbas A, et al. (2007). Reduced exposure to calcineurin inhibitors in renal transplantation. New Engl J Med, 357, 2562–75
   PubMed Web of Science ®Google Scholar
• Halloran PF. (2004). Immunosuppressive drugs for kidney transplantation. New Engl J Med, 351, 2715–29
   PubMed Web of Science ®Google Scholar
• Hariharan S, Johnson CP, Bresnahan BA, et al. (2000). Improved graft survival after renal transplantation in the United States, 1988 to 1996. New Engl J Med, 342, 605–12
   PubMed Web of Science ®Google Scholar
• Heilman RL, Younan K, Wadei HM, et al. (2011). Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. Transplantation, 92, 767–73
   PubMed Web of Science ®Google Scholar
• Holdaas H, Rostaing L, Seron D, et al. (2011). Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation, 92, 410–18
   PubMed Web of Science ®Google Scholar
• Hurst FP, Belur P, Nee R, et al. (2011). Poor outcomes associated with neutropenia after kidney transplantation: analysis of United States renal data system. Transplantation, 92, 36–40
   PubMed Web of Science ®Google Scholar
• Isakova T, Xie H. Messinger S, et al. (2013). Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation. Amer J Transplant, 13, 100–10
   PubMed Web of Science ®Google Scholar
• Lebranchu Y, Thierry A, Toupance O, et al. (2009). Efficacy on renal function of early conversion from cyclosporine to Sirolimus 3 months after renal transplantation: concept study. Amer J Transplant, 9, 1115–23
   PubMed Web of Science ®Google Scholar
• Mannon RB. (2006). Therapeutic targets in the treatment of allograft fibrosis. Amer J Transplant, 6, 867–75
   PubMed Web of Science ®Google Scholar
• Matas AJ, Leduc R, Rush D, et al. (2010). Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study. Amer J Transplant, 10, 315–23
   PubMed Web of Science ®Google Scholar
• Matas AJ, Smith JM, Skeans MA, et al. (2014). OPTN/SRTR 2012 Annual Data Report: kidney. Ame J Transplant, 14, 11–14
   PubMed Web of Science ®Google Scholar
• Matas AJ. (2011). Chronic progressive calcineurin nephrotoxicity: an overstated concept. Amer J Transplant, 11, 687–92
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche HU, Schold JD, Kaplan B. (2004). Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Amer J Transplant, 4, 1289–95
   PubMed Web of Science ®Google Scholar
• Morales JM, Wramner L, Kreis H, et al. (2002). Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Amer J Transplant, 2, 436–42
   PubMed Web of Science ®Google Scholar
• Mulay AV, van Walraven C, Knoll GA. (2009). Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis. Amer J Transplant, 9, 804–11
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DRJ, Sarwal M. (2009). Calcineurin inhibitor nephrotoxicity. Clin J Amer Soc Nephrol, 4, 481–508
   PubMed Web of Science ®Google Scholar
• Nankivell BJ, Borrows RJ, Fung CLS, et al. (2004). Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation, 78, 557–65
   PubMed Web of Science ®Google Scholar
• Peddi VR, Wiseman A, Chavin K, et al. (2013). Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation. Transplant Rev, 27, 97–107
   Web of Science ®Google Scholar
• Sayegh MH, Carpenter CB. (2004). Transplantation 50 years later—Progress, challenges, and promises. New Engl J Med, 351, 2761–6
   PubMed Web of Science ®Google Scholar
• Schena FP, Pascoe MD, Alberu J, et al. (2009). Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-Month efficacy and safety results from the CONVERT trial. Transplantation, 87, 233–42
   PubMed Web of Science ®Google Scholar
• Schold JD, Kaplan B. (2010). The elephant in the room: failings of current clinical endpoints in kidney transplantation. Amer J Transplant, 10, 1163–6
   PubMed Web of Science ®Google Scholar
• Schold JD, Meier-Kriesche HU. (2006). Which renal transplant candidates should accept marginal kidneys in exchange for a shorter waiting time on dialysis? Clin J Amer Soc Nephrol, 1, 532–8
   PubMed Web of Science ®Google Scholar
• Weir MR, Mulgaonkar S, Chan L, et al. (2011). Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Inter, 79, 897–907
   PubMed Web of Science ®Google Scholar
• Woodle ES, First MR, Pirsch J, et al. (2008). A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg, 248, 564–77
   PubMed Web of Science ®Google Scholar
• Yates CJ, Fourlanos S, Hjelmesaeth J, et al. (2012). New-onset diabetes after kidney transplantation: changes and challenges. Amer J Transplant, 12, 820–8
   PubMed Web of Science ®Google Scholar